Fang Wen-Feng, Chen Yu-Mu, Lin Chiung-Yu, Huang Kuo-Tung, Kao Hsu-Ching, Fang Ying-Tang, Huang Chi-Han, Chang Ya-Ting, Wang Yi-His, Wang Chin-Chou, Lin Meng-Chih
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Niaosung, Kaohsiung, Taiwan.
Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
PLoS One. 2017 Jul 10;12(7):e0179749. doi: 10.1371/journal.pone.0179749. eCollection 2017.
Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU.
A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016.
Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p < 0.001), hypertension (p < 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke (p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)-10 levels (p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) (p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals).
Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer.
癌症患者和脓毒症患者均存在免疫麻痹现象。在癌症患者中,细胞毒性T淋巴细胞抗原4以及程序性死亡蛋白1/程序性死亡配体1轴是免疫麻痹的两个关键组成部分。针对这两个轴的几种新兴疗法已取得显著临床疗效。在严重脓毒症患者中,免疫麻痹被称为代偿性抗炎反应综合征,这被认为是脓毒症患者死亡的一个重要原因。探究合并或未合并活动性癌症的严重脓毒症患者的免疫状态是否存在差异将会很有意思。本研究的目的是评估入住重症监护病房(ICU)的合并或未合并癌症的严重脓毒症患者的免疫谱差异及临床结局。
对2013年8月至2016年6月期间入住台湾高雄长庚纪念医院三个内科ICU的成年脓毒症患者队列进行回顾性和前瞻性联合观察研究。
在入住ICU的2744例患者中,纳入了532例脓毒症患者。根据病史将患者分为合并或未合并活动性癌症两组。在这532例患者中,95例(17.9%)有活动性癌症,437例(82.1%)无活动性癌症病史。与无活动性癌症的患者相比,有活动性癌症的患者更年轻(p = 0.001)且患糖尿病(p < 0.001)、高血压(p < 0.001)、冠状动脉疾病(p = 0.004)、慢性阻塞性肺疾病(p = 0.002)或中风(p = 0.002)的可能性更小(均为p < 0.001)。与无活动性癌症的患者相比,有活动性癌症的患者还表现出更高的基线乳酸水平(p = 0.038)、更高的基线血浆白细胞介素(IL)-10水平(p = 0.040)以及更高的粒细胞集落刺激因子(G-CSF)升高趋势(p = 0.004)(均为p < 0.001)。有活动性癌症的患者的14天、28天和90天死亡率均高于无活动性癌症者(所有时间段P < 0.001)。
在入住ICU且患有脓毒症的患者中,合并活动性癌症者比未合并活动性癌症者的血浆IL-10基线水平更高、G-CSF升高趋势更明显且死亡率更高。